To save this page as a PDF, click this button and choose the PDF destination.
Rapid Abstract Presentations
1:15 - 2:15pm Friday, 8th October, 2021
Breaks Sessions
Moderators and Panelists Rana McKay, Sumanta Pal
Original research presentations along with Q&A
Potential Role of Seleno-L-Methionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Yousef Zakharia MD, Jessica Sieren, Ryan Reis, Rohan Garje, Maheen Rajput, Rob Humble, Andrew Bellizzi, Youcef Rustum
University of Iowa
Real-world treatment patterns and outcomes of front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab for metastatic clear cell renal cell carcinoma
Dr. Kevin Zarrabi MD, Dr. Elizabeth Handorf PhD, Dr. Benjamin Miron MD, Dr. Matthew Zibelman MD, Dr. Fern Anari MD, Dr. Pooja Ghatalia MD, Dr. Elizabeth Pliamack MD MS, Dr. Daniel Geynisman MD
Fox Chase Cancer Center
Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination
Jasnoor Malhotra BSc1, Sabrina Salgia MS1, Zeynep Zengin MD1, Luis Meza MD1, Jennifer Ely2, JoAnn Hsu BSc1, Erin Kelley2, Heather Mead2, Kalen Patel1, Matthew Feng1, Sweta Prajapati1, Alex Chehrazi-Raffle MD1, Ameish Govindarajan MD1, Ramya Muddasani DO1, Neal Chawla MD1, Nazli Dizman MD1, Nicholas Salgia BSc1, Tanya Dorff MD1, Yung Lyou MD1, Ewa Karczewska1, Jeffrey Trent PhD3, Ravi Salgia MD, PhD1, John Altin PhD2, Sumanta Pal MD1
1City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 2Translational Genomics Research Institute North, Flagstaff, AZ, USA. 3Translational Genomics Institute, Phoenix, AZ, USA
Histologic Growth Patterns in Nephrectomy Specimens of Clear Cell Renal Cell Carcinoma Inform Tumor Evolution
Nicolas Sayegh MD1, Jonathan Chipman PhD2,3, Haoran Li MD, PhD1, Marc Barry MD4, Dan Albertson MD4, Jon Mahlow MD4, Ting Liu MD4, Prayushi Sharma2, Neeraj Agarwal MD1, Beatrice Knudsen MD, PhD1,4, Deepika Sirohi MD4
1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 3Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA. 4Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA
Transcriptomic analysis predicts resistance and toxicity in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)
Mrs Lucia Carril-Ajuria MD1,2, Mrs Alejandra Bernardini PhD3,4, Mrs Carolina Rubio PhD3,5, Mr. Alberto Carretero-González MD1, Mrs Maricruz Martin Soberon MD1, Mr Jose Luis Rodriguez Peralto MD6, Mr Daniel Castellano MD1, Mr Jesus Paramio PhD3,5, Mr Guillermo de Velasco MD, PhD1,4
1Medical Oncology Department, University Hospital 12 de Octubre. 2Institute Gustave Roussy. 3CIEMAT and Biomedical Research, University Hospital 12 de Octubre.. 4. 5CIBERONC. 6Department of Pathology, University Hospital 12 de Octubre
Ultra-sensitive ctDNA distinguishes complete response (CR) and partial response (PR) with immunotherapy in metastatic renal cell carcinoma (mRCC) patients
Alexander Chehrazi-Raffle MD1, Ramya Muddasani DO1, Nazli Dizman MD1, Paulo Bergerot MD1, JoAnn Hsu1, Zeynep Zengin MD1, Nicolas Salgia1, Sabrina Salgia1, Jasnoor Malhotra1, Neal Chawla MD1, Yung Lyou MD, PhD1, Tanya Dorff MD1, Tania Contente-Cuomo2, Devin Dinwiddie2, Bradon McDonald PhD3, Timothy McDaniel PhD2, Jeffrey Trent PhD2, Muhammed Murtaza MBBS, PhD2,3, Sumanta Pal MD1
1City of Hope Comprehensive Cancer Center. 2Translational Genomics Research Institute, an affiliate of City of Hope. 3University of Wisconsin, Division of Surgical Oncology
Seq-ing the source of radiation-induced anti-tumor immunogenicity in renal cell carcinoma patient tumors
Jacky Chow, Madeline Gaudieri, Scott Abrams, Thomas Schwaab, Anurag Singh, Jason Muhitch
Roswell Park Comprehensive Cancer Center
Multiplex analysis of the tumor microenvironment (TME) in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response
Mr. Nicholas Salgia BSc1, Dr. Haiqing Li PhD2, Mr. Isa Mambetsariev BA1, Dr. Nazli Dizman MD1, Dr. Zeynep Zengin MD1, Dr. Tamara Mirzapoiazova MD, PhD1, Dr. Dan Zhao MD, PhD1, Dr. Prakash Kulkarni PhD1, Dr. Sumanta Pal MD1
1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center. 2City of Hope Comprehensive Cancer Center